Age of combination therapy in the treatment of advanced RCC: can we do it better?
A Talk by Che-Kai Tsao (Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA)
Proudly supported by
About this Talk
A number of treatment options has been accepted for the first line treatment of metastatic clear cell renal cell carcinoma (mccRCC), but without cross comparison trials or validated biomarkers to guide treatment selection, clinician rely on their own experience, comfort level, and cross comparison of individual clinical data to pick the “best treatment” for their patient. Additionally, the optimal sequence of available therapies are poorly defined, and the best approach to maximize clinical benefit is unclear. We will review the current evidence guiding therapeutic selection in treatment of patients with mccRCC, and further discuss ongoing investigation in defining the optimal treatment paradigm.